In conclusion, this study identified multifocal lesions, larger tumor size, and higher WHO grade as independent adverse prognostic factors in glioma, while chemotherapy, IDH1/2 mutations, and MGMT promoter methylation were associated with improved survival. This evidence concerns the gene MGMT and central nervous system cancer.